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The Phosphatase and Tensin homolog detected on chromosome Ten PTEN displays tumor suppressive functions 
within two different cellular compartments. In the cytoplasm/membrane, it controls cellular proliferation, 
survival and metabolisms, through the de-phosphorylation of the phosphatidylinositol (3,4,5) triphosphate 
(PIP3), therefore counteracting the PI3K-AKT pathway. In the nucleus, it regulates proliferation and genomic 
stability through phosphatase independent mechanisms. Chronic Myeloid Leukemia is a myeloproliferative 
disorder generated by the translocation t(9;22), which encodes for the chimeric protein BCR-ABL. PTEN was 
shown to play an essential role in CML pathogenesis in a murine model. We and others have demonstrated that 
PTEN is affected in human CML though non genomic loss of function mechanisms. Furthermore, we proposed 
strategies to reactivate PTEN in CML cells, with relevant therapeutic implications.  
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Introduction 
The Phosphatase and Tensin homolog detected on 
chromosome Ten PTEN is one the most important tumor 
suppressor, with mutation/deletion rates similar to those of 
p53 in all cancers [1]. Recently, the mechanism of tumor 
suppressor involvement in cancer has been completely 
revised [2,3]. Original observations by Knudson supported the 
model whereby a tumor suppressor plays a role in cancer 
pathogenesis when both alleles are genetically affected, 
generally one by point mutations and one by deletions. 
Observations in murine models and human cancers have 
suggested that even genetically wild-type tumor suppressors 
can be involved in cancer pathogenesis [4,5]. In particular, 
reduction of tumor suppressor protein levels, changes in 
protein compartmentalization or post-trasductional 
modifications can functionally inhibit tumor suppressor 
functions [6–8]. These observations could have tremendous 
implications from the therapeutic standpoint.  The discovery 
of mechanisms that promote tumor suppressors inactivation 
could indeed be directly targeted to promote normalization of 
protein level, localization or protein status. These events 
could lead to a selective strong apoptosis induction in cancer 
cells without affecting normal cells [9]. Chronic Myeloid 
Leukemia is a challenging disease to test this model [10]. 
CML is a myeloproliferative disorder characterized by the 
translocation t(9;22) coding for the chimeric protein 
BCR-ABL [11]. CML is referred as an unique cancer, due to 
the fact that no tumor suppressors have been found 
mutated/deleted in the early stages of CML pathogenesis [12]. 
Furthermore, expression of BCR-ABL was considered 
sufficient to promote leukemogenesis [13], suggesting that 
BCR-ABL expression could somehow promote tumor 
suppressors inactivation. Notably, Peng and colleagues 
demonstrates that PTEN plays an important role in the 
pathogenesis of CML, in a murine model [14]. In human 
CML, PTEN was never shown mutated or deleted during the 
chronic phase of the disease [15]. Following these 
observations, we aimed to demonstrate that BCR-ABL 
functionally inactivates PTEN in CML.  
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Mechanisms of PTEN functional inactivation in CML 
BCR-ABL promotes PTEN nuclear-exclusion in CML 
Changes in the proper cellular compartmentalization of 
tumor suppressors have been reported to play an essential 
and druggable role among non genomic loss of function 
mechanisms that inactivate tumor suppressors [16]. In 
particular, PTEN, p53 and FoxOs have been shown to 
display different tumor suppressive functions accordingly to 
their cellular compartmentalization [16]. PTEN loss of nuclear 
pool was indeed associated with disruption of PTEN nuclear 
suppressive function [17–19].  In line with these 
considerations, while we were assessing PTEN cellular 
compartmentalization in CML, we discovered that CML 
progenitor cells and differentiated cells were characterized by 
PTEN nuclear exclusion [20,21]. We demonstrated that 
BCR-ABL regulates PTEN localization through a 
PML/HAUSP network. Strikingly, CML stem cells 
expressed physiological cytosol/nuclear diffuse PTEN 
localization, due to high levels of expression of the HAUSP 
regulator PML. These observations demonstrated that PTEN 
is functionally inactivated through the loss of nuclear pool in 
CML. Furthermore, we also showed that 
PML/HAUSP/PTEN network can be targeted by arsenic 
trioxide treatment, which in turn promotes CML stem cell 
exhaustion [20,22]. 
PTEN protein levels are reduced in primary CML cells 
BCR-ABL expression was associated with PTEN protein 
down-regulation [23]. Recently, we and others have 
demonstrated that PTEN is under-expressed in primary CML 
samples [24,25]. Similarly to oncogenic Ras regulation of 
PTEN levels [26], we observed that BCR-ABL regulates 
PTEN expression through a Ras-MEK pathway [25]. Notably, 
treatment with MEK inhibitors was associated with 
restoration of PTEN levels in BCR-ABL-infected cells. 
Interestingly, BCR-ABL mediated cellular transformation 
was also associated with the expression of a long non coding 
RNA, which is able to regulate PTEN expression, suggesting 
a more complex mechanism of PTEN expression regulation 
in CML [27]. These data further highlight how mechanisms of 
regulation of PTEN expression could play an essential role in 
the pathogenesis of CML.  
PTEN is inactivated in CML 
Our observation that PTEN is delocalized into the cytosol 
of CML primary cells suggested that PTEN could affect 
PI3K-AKT pathway in CML. This hypothesis was in contrast 
with the observations that PI3K-AKT plays an essential 
signaling transduction role in BCR-ABL-mediated 
transformation [28,29]. To solve this controversy, one simple 
explanation could be that the reduction of PTEN levels in 
CML counter-acts the effects of delocalized PTEN toward 
PI3K. However, PTEN activity was also shown to be 
regulated by post-trasductional modifications [4,8]. In 
particular tail phosphorylation by Casein Kinase II was 
shown to inhibit PTEN activity [30]. In line with these 
considerations, we observed that PTEN is highly 
tail-phosphorylated on serine residues by Casein Kinase II, a 
BCR-ABL substrate. BCR-ABL/Casein Kinase II-mediated 
PTEN phosphorylation eventually results in PTEN 
inactivation [31].  These data are important from the 
therapeutic standpoint. Treatment with Casein Kinase II 
inhibitors is indeed able to promote PTEN 
de-phosphorylation and activation toward PI3K-AKT 
pathway, with apoptosis induction. 
Conclusions 
All together, these data demonstrate that CML is 
characterized by PTEN functional inactivation at different 
layers. BCR-ABL promotes PTEN delocalization through a 
PML/HAUSP network, PTEN under-expression, through 
Ras-MEK, and PTEN inactivation by Casein Kinase II 
mediated phosphorylation of PTEN tail. These phenomena 
likely coexist in the regulation of PTEN activity. 
Importantly, the BCR-ABL/PTEN network has important 
implications from the therapeutic standpoint. We indeed 
demonstrate that PTEN proper cellular compartmentalization 
could be restored by targeting PML, which is a physiological 
regulator of HAUSP, PTEN levels could be restored by MEK 
inhibitors and PTEN activity can be increased with Casein 
Kinase II inhibitors treatment. All these strategies are 
associated with CML growth arrest and apoptosis induction. 
Future efforts are require to better characterize the relevance 
of BCR-ABL/PTEN network in different CML cellular 
populations. Data regarding PTEN cellular 
compartmentalization have been indeed performed in sorted 
progenitors cells and stem cells, showing significant 
differences. Data regarding PTEN protein levels and activity 
are on the contrary observed in un-sorted cells. Therefore, 
due to the heterogeneity of CML cells, it could be that PTEN 
nuclear exclusion, PTEN down-regulation and PTEN 
inactivation are differentially regulated by BCR-ABL in 
CML. This situation could have important biological 
consequences and therapeutic implications. 
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